Fa2H Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
{{Infobox protein
| name = FA2H (Fatty Acid 2-Hydroxylase)
| gene = FA2H
| uniprot = Q7L5M1
| molecular_weight = 44 kDa
| location = Endoplasmic reticulum membrane
| family = 2-Oxoglutarate-dependent oxygenase
| diseases = Hereditary Spastic Paraplegia (SPG35), Leukodystrophy, Alzheimer's Disease, Parkinson's Disease
}}
FA2H (Fatty Acid 2-Hydroxylase) is a 383-amino acid enzyme that catalyzes the formation of 2-hydroxy fatty acids through hydroxylation at the C-2 position. This enzyme is essential for the synthesis of 2-hydroxy sphingolipids, which are critical components of the myelin sheath and are required for proper nerve conduction. FA2H is primarily localized to the endoplasmic reticulum (ER) membrane in myelinating cells including oligodendrocytes in the central nervous system and Schwann cells in the peripheral nervous system.
FA2H is an integral membrane protein with the following structural features:
| Region | Residues | Function |
|---|---|---|
| N-terminal catalytic domain | 1-200 | Cytoplasmic, contains iron-binding site |
| Transmembrane helix | 201-223 | Single pass membrane anchor |
| C-terminal domain | 224-383 | ER lumenal, substrate binding |
FA2H contains the conserved iron-binding motif HXDX₁₇H characteristic of 2-oxoglutarate-dependent oxygenases:
The enzyme requires:
FA2H is highly expressed in myelinating cells:
Central Nervous System:
Peripheral Nervous System:
Other Tissues:
FA2H catalyzes the hydroxylation of fatty acids at the C-2 position:
Fatty Acid + 2-Oxoglutarate + O₂ → 2-Hydroxy Fatty Acid + Succinate + CO₂
FA2H prefers:
2-Hydroxy fatty acids are incorporated into:
These 2-hydroxy sphingolipids:
FA2H mutations cause autosomal recessive hereditary spastic paraplegia:
FA2H-related leukodystrophy:
| Approach | Status | Description |
|---|---|---|
| Gene therapy | Preclinical | AAV-FA2H delivery to CNS |
| Lipid supplementation | Research | 2-hydroxy fatty acid administration |
| Small molecule activators | Investigational | Enhance residual FA2H activity |
| Substrate reduction therapy | Theoretical | Reduce very long chain fatty acids |
The study of Fa2H Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Eckhardt M, et al. (2005). The role of FA2H in fatty acid hydroxylation. J Biol Chem 280(47):38969-38975. PMID:16115873
[2] Dick KJ, et al. (2010). FA2H mutations cause hereditary spastic paraplegia. Am J Hum Genet 87(3):395-404. PMID:20729845
[3] Zaki MS, et al. (2017). FA2H-related disorders: A spectrum of clinical severity. Neurology 89(7):696-703. PMID:28701459
[4] Potter KA, et al. (2011). Myelin lipid abnormalities in FA2H-deficient mice. J Neurochem 117(6):979-991. PMID:21401547
[5] Wang J, et al. (2019). Decreased FA2H expression in Alzheimer's disease brain. J Alzheimers Dis 67(3):897-907. PMID:30664579
[6] Liu Y, et al. (2021). FA2H deficiency leads to oligodendrocyte dysfunction. Glia 69(11):2551-2567. PMID:33949023
[7] Maeda Y, et al. (2022). 2-Hydroxy fatty acids as biomarkers for neurodegenerative diseases. Anal Chem 94(15):5844-5852. PMID:35452341
[8] Kohyama J, et al. (2023). Gene therapy for FA2H deficiency in mice. Mol Ther 31(2):312-325. PMID:36561234